Advancing impactful therapies for cardio­pulmonary diseases.

Catherine Pearce, M.B.A., D.HSc., is an innovative professional with over 25 years of experience focused on the biotech industry at various organizations. She founded AllRock in April 2024.

Dr. Pearce created and led the clinical stage biotech function of CinCor Pharma, Inc., from its formation through its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Prior to CinCor Pharma, she was co-founder and served as the Chief Operating Officer of CinRx Pharma, LLC where she was instrumental in building 6 portfolio companies including CinCor Pharma. Additionally, she has served as Vice President, Strategic Alliances at Medpace and Vice President, Research and Development at Teva Pharmaceutical Industries Ltd. She sits on a variety of corporate boards and provides strategic consulting for several biotech companies.

Dr. Pearce has demonstrated key skills in Clinical Project Management, R&D, and Business Development. She has successfully led many drug development programs, brought multiple marketed products to fruition, and established strategic alliances. Her strategic leadership and expertise have been pivotal in achieving major milestones, including the acquisition of CinCor Pharma by AstraZeneca. Additionally, Dr. Pearce’s expertise in biotech has helped numerous companies establish successful drug development and operational frameworks.

Dr. Pearce holds a B.S. and an M.B.A. from Xavier University and a Doctor of Health Sciences from Nova Southeastern University. In her personal life, she enjoys college basketball games, cooking big Italian meals, and golfing with her husband.

Justin R. Thompson, MS is an experienced professional with over 20 years of business development and strategic investments in the life sciences and venture capital industry. Justin founded AllRock in April 2024.

Justin led the business development function of CinCor Pharma, Inc., a clinical-stage biotech, from its formation through the in-licensing of baxdrostat from Roche, culminating in its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Justin, in conjunction with Dr. Pearce, led the in-licensing of baxdrostat in 2019. Prior to CinCor, he served as the Chief Business Officer at CinRx Pharma, LLC, leading additional licensing and venture transactions. He was also a Principal investor at CincyTech, LLC, a public-private seed-stage investor focused on high-growth life science and technology companies.

Justin has demonstrated key skills in business development, strategic investments, and leadership. He has successfully led the in-licensing of key assets, managed strategic partnerships, and driven significant growth and acquisitions. His strategic vision and leadership have been pivotal in achieving major milestones, including successful acquisitions and the establishment of robust investment frameworks. Additionally, Justin’s expertise in strategic investments has helped numerous life science companies establish strong financial and operational foundations.

Justin holds an M.S. from the University of Cincinnati and a B.S. from Washington University in St. Louis. In his personal life, he enjoys spending time with his family and almost anything outdoors.

Dr. Bill Marshall is a proficient clinician scientist with over 35 years of experience in academic medicine and subsequently focused on drug development at various organizations.

Prior to AllRock, Dr Marshall served as VP, Medical at CinCor leading the development of baxdrostat prior to its acquisition by AstraZeneca. Additionally, Dr. Marshall worked in the translational pharmacology division at Merck, a Fortune 500 pharmaceutical company, and spearheaded drug development from its formation through the design and oversight of Phase 1 and Phase 1b/proof of concept studies, culminating in several successful drug development programs. He has also held increasing leadership positions at Alexion, Allovir, reSTORbio Pharma, and others. He also worked as an Instructor of Medicine at Harvard Medical School and later as an Associate Professor of Medicine at the University of Massachusetts Medical School.

Dr. Marshall has demonstrated key skills in clinical development strategies, regulatory compliance, and team leadership. He has successfully overseen Phase 1 through Phase 3 multicenter and/or multinational trials in various indications such as neurology, endocrine/hypertension, aging, autoimmunity, and infectious disease. His strategic clinical development and leadership have been pivotal in achieving major milestones, including several regulatory approvals. Additionally, Dr. Marshall’s expertise in scientific discussions and publication strategies has helped numerous pharmaceutical companies establish efficient clinical frameworks.

Dr. Marshall holds an A.B. from Harvard University and a medical degree from Columbia University, College of Physicians and Surgeons. In his spare time, Bill chases after his six-year-old “puppy” DeeDee who is a half Shih Tzu, half Golden Doodle and all attitude.

Jack Greene is a dedicated professional with over 25 years of experience focused on drug substance, drug product, and CMC regulatory teams at various organizations.

Jack created and led the CMC function of CinCor Therapeutics, a clinical-stage biotech, through the complex manufacturing process of baxdrostat, culminating in its acquisition by AstraZeneca. Prior to CinCor, he served as Head of CMC at Anagram Therapeutics, and held positions at Allena Pharmaceuticals, Alcresta Therapeutics, Alnara (acquired by Eli Lilly & Co), Altus Pharmaceuticals, Alkermes, Genzyme, and Serono.

Jack has demonstrated key skills in CMC regulatory, process development of both NCE/NME and biologics drug substances, and formulation development of oral, parenteral, and inhalation drug products. He has successfully managed analytical development/QC and characterization, integrated commissioning and qualification of new manufacturing plants, and the design of integrated plant-wide process control systems. His strategic design, implementation, and validation of enterprise-level computer systems, including LIMS, SCADA, ERP/MRP, eQMS, and CMMS, have been pivotal in achieving major milestones. Additionally, Jack’s expertise in these areas has helped numerous pharmaceutical companies establish quality manufacturing frameworks.

Jack is an Organic Chemist by training and lives in Boston with his family.  In his spare time, he fixes broken things, cleans up messes, and combines these skills to restore vintage automobiles.

Andrea Ledford, CPA, is a devoted professional with over 20 years of experience focused on accounting and financial management at various organizations.

Andrea created and led the accounting function of CinCor Pharma, Inc., a clinical-stage biotech, from its formation through IPO, culminating in its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Prior to CinCor, she served as the Controller at CinRx Pharma, LLC, and Zipscene, a software development company. She also worked as an auditor at PWC and consulted for several biotech and startup companies.

Andrea has demonstrated key skills in financial strategy, investment strategy, GAAP and SOX compliance, leadership. She has successfully managed financial operations, led companies through significant growth phases, and ensured compliance with industry standards. Her strategic financial planning and leadership have been pivotal in achieving major milestones, including successful IPOs and acquisitions. Additionally, Andrea’s expertise in consulting has helped numerous startups establish robust financial frameworks.

Andrea holds an M.S. in Accounting and a B.S. in Business Administration from the University of North Carolina at Chapel Hill. In her personal life, she has a love for the theatre and has served on boards and directed several productions for various children’s theatres.

Serra Elliott, PhD, is a business development and corporate strategy professional with over eight years of experience working in the biotech industry.

Prior to joining AllRock Bio, Dr. Elliott held business development and alliance management roles of increasing responsibility at a number of biotech companies, including insitro, Pionyr Immunotherapeutics, and BlueLight Therapeutics. Her work at Insitro led to a unique collaboration with Lilly Catalyze360. At Pionyr, she played a crucial role in managing the company’s alliance with Gilead Sciences and the eventual acquisition by Ikena Oncology.

Dr. Elliott has a strong track record of negotiating key transactions, managing external partnerships, and driving corporate strategic initiatives. She has a proven ability to work cross-functionally to align internal and external stakeholders and combine scientific insight with business strategy across multiple therapeutic areas, including oncology and metabolic disease.

Dr. Elliott completed a postdoctoral fellowship in Immunology and Rheumatology at Stanford University. She holds a PhD in Chemical Engineering from the University of California, Santa Barbara, and a BS in Chemical Engineering from The Ohio State University. In her personal time, she enjoys hiking, traveling, cooking, and spending time with her family.

Dr. M. Kathryn Steiner (Kate), B Med Sci, MBBS is a physician scientist, currently focused on drug development, with over 25 years of clinical academic experience in PAH animal modeling, PAH investigator-initiated trials and providing sub-specialization care for patients with end stage lung disease as both a pulmonologist and critical care physician.

Prior to AllRock Bio, Dr Steiner served as Medical Director at Keros Therapeutics, leading the phase II trial of an activin receptor type II B ligand trap to treat pulmonary artery hypertension, providing subject matter expertise and achieving rapid patient enrollment. She successfully coordinated with regulatory teams, steering and safety review committees to ensure compliance, quality evidence-based science, and patient safety.  She also contributed to phase III strategy development plans, security and exchange filings, and board updates.   She has worked as an Instructor of Medicine at Harvard Medical School, an Assistant Professor of Medicine at the University of Massachusetts Medical School, and as Chief of Pulmonary Medicine overseeing noncardiac peri-operative medicine at the New England Baptist Hospital Beth Israel Lahey Health and is currently a part-time pulmonary critical care attending at Tufts Medical Center.

Dr. Steiner holds a bachelor’s in Medical Sciences from the University of St Andrews, Scotland, and a medical degree from St Bartholemew’s and the London Medical College, England. In her spare time, Kate juggles the needs of a dragon-obsessed 9-year-old, a fashion-obsessed 16-year-old, and a husband who spends part of his life in the Middle Ages.  She finds peace in the mountains, the ocean, and a good novel. 

Kenny Kamineni brings 20 years of experience in the pharmaceutical, biotech and medical device industries.  He oversees and directly manages CROs, clinical vendors and clinical studies across all Phases of Drug Development.  Prior to joining JucaBio, Kenny held positions in clinical operations within the rare disease and cardiovascular field, including Associate Director, Clinical Operations at AlloVir, Associate Director/Sr. Clinical Trial Manager at Ascendis Pharma, and Sr. CRA at St. Jude Medical. Throughout his career, with experience from both the clinical site and sponsor level, Kenny has successfully operationalized and implemented strategies in successful clinical trial conduct.

Kenny holds a Bachelor of Medicine & Bachelor of Surgery (MBBS) from Kempegowda Institute of Medical Sciences, Bangalore, India. In his free time, Kenny enjoys travelling the world, trying new delicacies, and playing with his dog, Daisy, a very energetic husky.